Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target Lead asset LX2006 is an AAVrh10-based gene therapy for Friedreich’s ataxia cardiomyopathy in pre-pivotal development, and Lexeo is also developing LX2020 as an AAVrh10-based gene therapy in PKP2 arrhythmogenic cardiomyopathy, the analyst tells investors in a research note. The firm applauds management’s approach to be transparent with frequent, quarterly safety updates, and thinks Lexeo could prove itself to be a leading cardiac-gene therapy company.